Physician profile
Katie E Schrack
NPI 1427217207
$6,584.15
in general payments reported to CMS, 2019-2025
26 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $369 · 2021: $860 · 2022: $927 · 2023: $891 · 2024: $1,138 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,330.20 | 2019-2025 | Clareon, Argos, Centurion |
| Sun Pharmaceutical Industries INC. | $852.76 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $695.23 | 2019-2023 | |
| Biotissue Holdings INC. | $619.77 | 2019-2025 | |
| Dompe US, INC. | $548.98 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $541.22 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $406.19 | 2024-2025 | Xdemvy |
| Allergan, INC. | $325.36 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $232.52 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $190.41 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Kala Pharmaceuticals, INC. | $123.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $116.61 | 2021 | |
| Mallinckrodt Hospital Products INC. | $96.13 | 2020-2025 | Acthar |
| Harrow Eye, LLC | $96.11 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $71.25 | 2024-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $70.54 | 2023-2025 | Via360, Streamline, Ahmed Glaucoma Valve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.04 | 2019-2021 | |
| Amgen INC. | $36.26 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $35.60 | 2024-2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $25.56 | 2019 | |
| Mallinckrodt Enterprises LLC | $23.97 | 2019 | |
| Eyevance Pharmaceuticals LLC | $23.50 | 2019 | |
| Akorn Operating Company LLC | $18.98 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Omeros Corporation | $16.07 | 2021 | |
| Apellis Pharmaceuticals, INC. | $13.86 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Schrack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.